The study is designed to demonstrate weight loss and quality of life at 12 months after the ESG procedure when compared to lifestyle modifications alone.
Employing real-time monitoring technologies to the chronic disease protocol, patients are empowered to become a part of addressing their own medical concerns.
Online ExclusivesWaqaas Al-Siddiq, Founder and CEO, Biotricity05.30.19
A non-surgical solution for obesity approved for one year of device treatment, offering patients potentially more durable weight loss and health benefits.
The registry will follow 1,500 patients worldwide for five years from the date of their first liver ablation procedure with the company's NEUWAVE System.
Johnson & Johnson Medical Devices Companies04.01.19
Trial is designed to measure the efficacy and safety of EndoBarrier in conjunction with lifestyle therapy and diabetes medication for type 2 diabetes treatment.
New hire brings over 30 years of experience in development, regulatory, preclinical and clinical operations, quality and resource management to the position.